Manchester Institute of Biotechnology, School of Chemistry, Faculty of Science and Engineering, University of Manchester
Professor of Synthetic Biology
131 Princess Street
+44 (0)161 306 4419
Eriko Takanois Professor in Synthetic Biology at the University of Manchester since 2012. She is internationally renowned as one of the leaders in the application of synthetic biology approaches to high-value secondary metabolite production using actinomycetes and working across Bioscience-Computational Science-Chemistry-Engineering disciplines. She is establishing an innovative toolbox for the discovery of new antibiotics and guiding SynBio approaches towards additional chemical novelty. She led the development of the antibiotics analysis software antiSMASH, now widely used by the natural products research community. Since appointment in Manchester she has won grants totalling >£5M and has a current funding from BBSRC and EPSRC in excess of £3M. She has experience in coordinating large multidisciplinary research programs, e.g., as H2020 coordinator for TOPCAPI (http://topcapi.eu/), PI/Director of Manchester Synthetic Biology Research Centre, SYNBIOCHEM (http://synbiochem.co.uk/), and as coordinator for ERA-IB TERPENOSOME. She is also involved in strategic and operational planning through her role as deputy head of School of Chemistry and section head of Chemical Biology and Biological Chemistry at the University of Manchester. She has a prolific publication record with 87 peer-reviewed papers since 1993 (h-index 39 with 6688 citations), numerous book chapters, and four international patents.
The University of Manchester (UoM) is the largest single-site university in the UK, with research strength across all scientific disciplines. UoM has an excellent reputation as an international centre for scholarship and research and has the largest number of national and international students in the UK, ranking in the top 5 for research power, with the highest quality teaching, and the broadest spread of academic subjects. Research is at the heart of UoM, and the scale, diversity and quality of its research activity is unrivalled in the UK. No fewer than 25 former staff and students have gone on to become Nobel Prize winners, and the University currently has 2 Nobel laureates as members of academic staff. The University has an annual income of more than £1 billion, with over £260m of research funding earned each year, a staff of over 12,000 including over 6,600 academic and research staff, and a student population (made up of over 30 per cent graduates) of over 40,000.
Eriko Takano is based in the Manchester Institute of Biotechnology (MIB, http://www.mib.ac.uk/), which is a cross faculty Institute and provides modern state-of-the-art laboratories, designed to facilitate research across chemistry and biological sciences, especially in the area of Industrial Biotechnology including applications in the synthesis of fine chemicals and pharmaceuticals. MIB is globally networked with industrial and academic groups and has a range of complementary skill sets that can make a critical contribution to the catalytic ideas and strategic plans for the JPIAMR-VR. The MIB has more than 45 PIs in multiple disciplines and is home to analytical and structural biology facilities adjacent to biology laboratories with all the required molecular biology technologies, supported by a strong research focus in systems and computational biology. Takano is a PI in the £12M BBSRC/EPSRC-funded Manchester Synthetic Biology Research Centre SYNBIOCHEM, which provides SynBio facilities, technology platforms for the discovery and reengineering of biocatalyst building blocks and pathways/cells to produce bioactive compounds which include HTP robotics, microfluidics (picodroplet), MicroCal Auto-ITC, and analytical equipment (QExactive, Ion Mobility Q-TOF, Triple Quadrupole LC/MS, MALDI-TOF) required for an innovative research platform for antimicrobial drug discovery and development. The centre provides an excellent environment for training early career researchers in industrial biotechnology, contributing to the important translational aspects of AMR research.
Eriko Takano is internationally renowned as one of the leaders in the application of SynBio to high-value secondary metabolite production using actinomycetes and working across Bioscience-Computational Science-Chemistry-Engineering disciplines. She is establishing an innovative toolbox for the discovery of new antibiotics and guiding SynBio approaches towards additional chemical novelty. She led the development of the antibiotics analysis software antiSMASH, now widely used by the natural products research community. She will contribute to the network through this innovative toolbox of collaborative research tools, her recognized expertise in Streptomyces genetics, and groundbreaking work on integrating synthetic biology into the pipeline for novel antimicrobial discovery.